Glucagon-like peptide 1 (GLP-1)-based therapy upregulates LXR-ABCA1/ABCG1 cascade in adipocytes

GLP1-mimetic/DPP-4 inhibitor act either directly (through GLP-1R) or indirectly (by restoring DPP-4-induced signaling impairment) to activate Ras/MAPK/ERK signaling which stimulate LXR-α to upregulate ABCA1/ABCG1 ultimately increasing cholesterol efflux.